Introduction
============

Arrhythmia is one of the most common cardiovascular complications during anesthesia. Its occurrence has been reported in 70% of patients undergoing general anesthesia for various surgical procedures \[[@B1][@B2]\]. Patients undergoing cardiac surgeries are more vulnerable to arrhythmia. Intraoperative arrhythmia is clinically important because it can be associated with significant hemodynamic instability. In this manuscript, we explain the mechanism, diagnosis, and treatment of intraoperative critical arrhythmias other than ischemia-related arrhythmia.

Normal Sinus Rhythm and Anti-arrhythmic Agents
==============================================

To understand arrhythmia, the definition of normal sinus rhythm should be understood. Normal cardiac electrical conduction occurs as follows: the cardiac impulse begins in the sinoatrial (SA) node and travels to both atria; the atria depolarize and generate the P wave; the impulse travels to the atrioventricular (AV) node, where the speed is reduced; the impulse through the AV node travels down the His bundle and Purkinje fibers; and finally, the impulse of the Purkinje fibers rapidly distributes and depolarizes the ventricles and generates the QRS wave. Therefore, the normal sinus rhythm is conventionally defined as the result of normal cardiac electrical conduction with normal shapes of waves, normal duration of intervals, and a rate between 60 and 100 beats/min for adults.

Normal cardiac electrical conduction starts from the cardiac action potential, and is generated by the movements of ions through ion channels in the cardiac cells. The action potential of the myocardium is composed of five phases, and the activation of ion channels at each phase is distinct ([Fig. 1](#F1){ref-type="fig"}). The mechanism of arrhythmia is roughly divided into three categories \[[@B3]\]: 1) increased automaticity due to reduced threshold of the action potential or increased slope of phase 4 depolarization; 2) triggered activity due to afterdepolarization reaching the threshold of the action potential; and 3) circus movement or re-entry. Arrhythmia does not need instant treatment if it is not accompanied by hemodynamic instability. Arrhythmia can make the heart pump ineffectively, and can produce blood clots. Therefore, the goals of treatment are prevention of blood clots to reduce the risk of stroke, control of the heart rate (HR) within a relatively normal range, restoration of normal HR if possible, correction of the condition that caused the arrhythmia, and reduction of other risk factors for heart disease and stroke. If arrhythmia occurs, the problem exists in the process of the cardiac action potential with electrical conduction. Therefore, the agents for control of cardiac action potential with electrical conduction are anti-arrhythmic agents. The type of anti-arrhythmic agent is classified based on the action site of the ion channel ([Table 1](#T1){ref-type="table"}).

Causes of Intraoperative Arrhythmia
===================================

The causes of intraoperative arrhythmia can be divided into three groups: patient, surgical procedure, and anesthesia. Patients with cardiac disease have a much higher incidence of intraoperative arrhythmia than those without. Patients with intracranial disease may show electrocardiographic (ECG) abnormalities. Postoperative atrial fibrillation occurs more often in elderly patients compared to younger patients. Cardiac surgery, including direct surgical manipulation and procedures related to cardiopulmonary bypass, may precipitate arrhythmia. Dental surgery is often associated with arrhythmias due to profound frequent stimulation of the autonomous nervous system. Severe bradycardia due to the oculocardiac reflex during strabismus surgery commonly occurs, particularly in neonates and children. Direct or indirect stimulation of vagal tone in surgical procedures produces bradycardia or block. Various factors associated with anesthesia influence the occurrence of arrhythmia. Anesthetic agents themselves are arrhythmogenic. Evaluation of the influence of anesthetic agents on ventricular repolarization is important because the agents may cause malignant ventricular arrhythmias, such as torsade de pointes \[[@B4]\]. This topic is detailed in the next chapter. Abnormal blood gas or electrolytes, autonomic nervous stimulation, central venous cannulation, and so on can result in arrhythmia. The most common cause of intraoperative arrhythmia is endotracheal intubation, which accompanies hemodynamic disturbance by autonomic reflexes.

Anesthetic Agents and Arrhythmia
================================

Drug-induced prolonged ventricular repolarization is associated with torsade de pointes and sudden cardiac arrest \[[@B4]\]. Torsade de pointes is characterized by polymorphic QRS complexes twisting around the isoelectric line, and is typically related to QT interval prolongation and the R-on-T phenomenon \[[@B5]\]. ECG markers for QT interval \[[@B6]\], QT interval corrected with HR (QTc) \[[@B7][@B8][@B9][@B10]\], JT interval \[[@B11]\], QT dispersion (QTd) \[[@B12]\], QT variability index \[[@B13]\], and transmural dispersion of repolarization (TDR) are used to check for the possibility of torsade de pointes \[[@B14][@B15]\]. All of the inhaled anesthetic agents prolong QTc and QTd, whereas sevoflurane does not affect TDR \[[@B4]\]. Propofol does not significantly affect QTc, regardless of cardiovascular disease \[[@B16][@B17][@B18]\]. Opioids have no effects on QTc \[[@B4]\], but a high dose of sufentanil may produce QT interval prolongation \[[@B19][@B20]\]. Succinylcholine significantly prolongs the QT interval and QTc, particularly with thiopental \[[@B21][@B22]\], although most non-depolarizing neuromuscular blockers have not been associated with prolongation \[[@B23]\]. However, the combination of anticholinesterase and anticholinergics to reverse neuromuscular blockade causes transient but significant prolongation of QTc \[[@B24][@B25]\]. On the other hand, sugammadex is relatively safe \[[@B26][@B27]\]. Local anesthetic agents have no significant effects on QTc \[[@B28][@B29]\]; however, the level of blockade can influence ECG \[[@B30][@B31]\]. Interscalene brachial plexus block with ropivacaine or bupivacaine do not produce any change in QT interval or QTc \[[@B32]\]. Adjuvant agents related to anesthesia may be a cause for concern. The Food and Drug Administration issued a black box warning on droperidol, an anti-emetic agent, for sudden potential cardiac death \[[@B33]\]. Serotonin type 3 receptor antagonists, potent anti-emetic agents, are also associated with prolongation of QTc \[[@B34][@B35]\]. Consensus guidelines for the management of postoperative nausea and vomiting suggest that care should be taken when using those anti-emetic agents in patients with prolonged QT interval \[[@B36]\].

Identification of Intraoperative Arrhythmia and Management
==========================================================

The types of arrhythmia are classified by such factors as HR, mechanism, duration, and origin. For the identification of intraoperative arrhythmia and its management, the anesthesiologist should be aware of the following: 1) What is HR? 2) Is the rhythm regular or irregular? 3) Is one P present for each QRS? 4) Is the QRS normal? 5) Is the rhythm associated with hemodynamic instability? 6) Does the rhythm require treatment?

Sinus bradycardia and sinus tachycardia
---------------------------------------

Conventionally, sinus bradycardia is defined as HR \< 60 beats/min, and sinus tachycardia is defined as HR \> 100 beats/ min at resting state in adults. Generally, maximal HR is considered to be (220 − age) beats/min. Both arrhythmias have a regular rhythm, a ratio of P to QRS of 1 : 1, and a normal QRS, although severe sinus tachycardia is accompanied by ST depression. Because marked sinus bradycardia with HR \< 40 beats/min may be poorly tolerated in healthy patients, the causes should be identified before treatment of the arrhythmia for maintenance of cardiac output. The treatments of sinus bradycardia are all attempts to increase HR, including pacing. If the patient is stable, despite marked sinus bradycardia, close observation may suffice. However, in cases with signs of inadequate systemic perfusion, such as hypotension or electrocardiographic evidence of ischemia, pharmacologic therapy or temporary percutaneous pacing may be necessary. Intravenous atropine of 0.5 mg is used as first-line therapy for the treatment of bradycardia, and may need to be repeated every 3 to 5 min up to a total of 3 mg. If bradycardia persists despite intravenous atropine, positive chronotropic agents such as isoproterenol, dopamine, dobutamine, and epinephrine may be needed to increase HR. In some cases, bradycardia degenerates into asystole, and thus, immediate cardiopulmonary resuscitation is necessary. This serious circumstance can be induced by vagal reflex with venipuncture or epidural puncture. The most common cause of sinus bradycardia is autonomic disturbance including vasovagal stimulation. Hypoxia, hypothermia, endotracheal suctioning, and increased intracranial pressure are also associated with sinus bradycardia. Con-versely, the causes of sinus tachycardia include pain, fever, and hypercarbia. Sinus tachycardia is the most common arrhythmia occurring in the perioperative period. The most common cause of sinus tachycardia is hypovolemia or inadequate anesthetic depth, and the correction of these conditions is the first step in the treatment of sinus tachyarrhythmia. The treatments of sinus tachycardia are all attempts to decrease HR.

AV block
--------

Intraoperative AV block may occur in the settings of intrinsic cardiac disease, perioperative ischemia, electrolyte abnormalities, excessive vagal tone, or iatrogenic causes including surgical aortic valve replacement. Most cases of intraoperative AV block are transient and do not require pacing. However, this arrhythmia may be persistent or permanent, and thus, an epicardial pacing system is necessary when AV block develops in cardiac surgery, particularly in aortic or mitral valve surgery. AV block is classified as first, second, and third (complete) degree. First-degree AV block does not require treatment. In second-degree AV block, pacing may be required if bradycardia is severe or causes hemodynamic instability. Third-degree AV block is characterized by P waves that are discordant with QRS waves. Pacing is usually required because escape junctional or ventricular rhythm is usually very slow at \< 40 beats/min. This information is shown in [Fig. 2](#F2){ref-type="fig"}.

Paroxysmal supraventricular tachycardia (PSVT)
----------------------------------------------

PSVT has a regular rhythm, and a ratio of P to QRS of 1 : 1 with normal QRS at HRs of 130--270 beats/min. It also shows an ischemic change in ECG such as sinus tachycardia. The P wave may often be hidden in the QRS complex or T wave. The mechanism of PSVT is different from that of sinus tachycardia. PSVT occurs as the result of excessive stimulation of the SA node; atrial excitation outside of the SA node; AV nodal re-entry; and re-entry through a bypass tract. To rule out or differentiate PSVT from sinus tachycardia or atrial flutter/fibrillation, carotid sinus massage or intravenous injection of edrophonium 5--10 mg is applied. Recently, intravenous adenosine (6 mg) was shown to rapidly slow AV nodal function, and has been easily used to differentiate or treat PSVT. Theoretically, AV nodal re-entrant tachycardia and AV re-entrant tachycardia are terminated by intravenous adenosine. Up to 80% of atrial tachycardias may be terminated by adenosine. However, atrial flutter or atrial fibrillation was not terminated by adenosine. If the response to adenosine fails, a double dose of adenosine should be tested. For treatment, adenosine is the drug of choice. Other agents that decrease HR or cardioversion are used for the treatment of PSVT. If PSVT persists with focal atrial impulses or atrioventricular re-entry electrical ablation with radiofrequency energy can be performed. This information is shown in [Fig. 2](#F2){ref-type="fig"}.

Atrial flutter and fibrillation
-------------------------------

Atrial flutter has a regular rhythm, regular rhythm, and a P and QRS ratio of 2 : 1 or 3 : 1, with normal QRS at HRs of 250--300 atrial beats/min with 150 ventricular beats/min. The mechanism of atrial flutter is macro re-entrant arrhythmia, circulating in a specific manner in the right atrium. Atrial flutter with very fast HR is usually accompanied by AV block, manifesting 2 : 1--4 : 1 AV conduction. Classic saw-tooth waves, so-called F waves, are usually present. T waves are lost in F waves. The treatment of atrial flutter should be started after consideration of the existence of thromboembolism. Pharmacologic or synchronized cardioversion is used for treatment of atrial flutter. Atrial fibrillation has an irregularly irregular rhythm, and normal QRS at HRs of 350--500 atrial beats/min and 60--170 ventricular beats/min. The P wave is absent and is replaced by F waves. The mechanism of atrial fibrillation has been suggested to involve multiple electrical wavelets caused by abnormal foci, micro or macro re-entrant, and so on. Atrial fibrillation causes an excessively rapid and irregular atrial contraction with no obvious atrial kick. It is called irregularly irregular and may be associated with a pulse deficit. The significance of atrial fibrillation is that the loss of atrial kick is associated with reduction of left ventricular filling and stroke volume. Consequently, hemodynamic instability occurs. The loss of obvious atrial kick can produce atrial thrombi, resulting in pulmonary and systemic thromboembolism. The treatment of atrial fibrillation is similar to the treatment of atrial flutter. It should be noted that, if atrial fibrillation is present for longer than 48 h, attempts to restore sinus rhythm may increase the risk of thromboembolism. This information is shown in [Fig. 2](#F2){ref-type="fig"}.

Premature ventricular contraction (PVC)
---------------------------------------

PVC has an irregular rhythm. It has no associated P wave because PVC results from ectopic pacemaker activity arising below the AV node. PVC also has a wide (\> 0.12 second) and bizarre QRS, because it originates in and spreads through the myocardium or ventricular conducting system. PVC is frequently observed during anesthesia. Its clinical significance is limited. However, a new onset of PVC should be considered a potentially serious event as it may lead to ventricular tachycardia/fibrillation. This information is shown in [Fig. 3](#F3){ref-type="fig"}.

Ventricular tachycardia (VT) and ventricular fibrillation (VF)
--------------------------------------------------------------

If three or more sequential PVCs are present, it is defined as VT. VT shows fusion, capture beats, and atrioventricular dissociation in an ECG. VT has a regular rhythm at HRs of 100--200 beats/min. The ratio of P and QRS has no fixed relationship because of atrioventricular dissociation. VT is a life-threatening state and needs emergent treatment. Amiodarone is recommended for treatment. Amiodarone is a type III anti-arrhythmic agent, but it also has the properties of I, II, and IV. Intravenous administration of amiodarone (150 mg) for longer than 10 min is used for a loading dose. After the loading dose, 1 mg/min for 6 h and 0.5 mg/min for 18 h is followed by dose reduction or administration by the oral route. Synchronized cardioversion is applied for hemodynamic instability. VF has an irregular and grossly disorganized HR, totally irregular rhythm, and no relationship between P and QRS. The QRS is absent. It means that no effective cardiac contraction with output exists. Immediate cardiopulmonary resuscitation is required. A non-synchronized defibrillation with 200--360 J is used. Biphasic shock reduces the required energy level and increases the efficacy of defibrillation. Magnesium sulfate may facilitate defibrillation. Epinephrine can be used to coarsen fibrillation just before defibrillation. It can also facilitate defibrillation. This information is shown in [Fig. 3](#F3){ref-type="fig"}.

Torsade de pointes
------------------

Torsade de pointes is usually invoked in the situation of prolonged QT interval or bradycardia. Therefore, the anesthesiologist should check the baseline QT interval and check for drugs that prolong QT interval before operation because prolongation of QT interval may increase the risk for torsade de pointes. Many anesthetic agents may cause mild prolongation of the QT interval, but are not likely to cause torsade de pointes, although some case reports of intraoperative torsade de pointes under specific anesthetic agents have been published \[[@B37][@B38]\]. Therefore, anesthesiologists should pay special attention to the changes in QT interval and HR during anesthesia. If the patient is hemodynamically unstable, defibrillation should be delivered promptly. However, if the patient has recurrent non-sustained episodes of torsade de pointes in the perioperative period, first-line therapy is administration of magnesium sulfate 2 g as a slow intravenous bolus. This information is shown in [Fig. 4](#F4){ref-type="fig"}.

Artifacts
=========

In some cases, such as patient movement and electrocautery, artifacts in ECG monitoring can lead anesthesiologists to misinterpret ECGs as indicating atrial fibrillation or VF ([Fig. 5](#F5){ref-type="fig"}). In these situations, the anesthesiologist should check the patient\'s vital signs, particularly arterial pulse or arterial blood pressure monitoring, and correct the potential causes that can induce artifacts.

Conclusions
===========

Intraoperative arrhythmia can occur under any circumstances during anesthesia. If it occurs, the anesthesiologist should identify the precipitating factors and manage them, even if the arrhythmia is not associated with hemodynamic instability. The understanding of intraoperative arrhythmia on an electrophysiologic and pharmacologic basis can help anesthesiologists easily manage this condition.
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###### Anti-arrhythmic Agents
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  Class   Basic mechanism              Comments                                                                                                             Drugs                                                                                                Uses
  ------- ---------------------------- -------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ----------------------------------------------
  I       Sodium-channel blockade      Reduce phase 0 slope and peak of action potential                                                                                                                                                                         
   IA     Moderate                     Moderate reduction in phase 0 slope; increase action potential duration; increase effective refractory period.       Quinidine, procainamide, disopyramide                                                                Ventricular arrhythmias, atrial fibrillation
   IB     Weak                         Small reduction in phase 0 slope; reduce action potential duration; decrease effective refractory period.            Lidocaine, tocainide, mexiletine                                                                     Ventricular arrhythmias
   IC     Strong                       Pronounced reduction in phase 0 slope; no effect on action potential duration or effective refractory period.        Flecainide, propafenone                                                                              Paroxysmal atrial fibrillation
  II      Beta-blockade                Block sympathetic activity; reduce rate and conduction                                                               Acebutolol, atenolol, bisoprolol, esmolol, metoprolol, nadolol, propranolol, carvedilol, labetalol   
  III     Potassium-channel blockade   Delay repolarization (phase 3) and thereby increase action potential duration and effective refractory period        Sotalol, dofetilide, ibutilide, bretylium, amidodarone                                               Ventricular arrhythmias, atrial fibrillation
  IV      Calcium-channel blockade     Block L-type calcium-channels; most effective at sinoatrial and atrioventricular nodes; reduce rate and conduction   Amlodipine, felodipine, isradipine, nicardipine, nifedine, diltiazem, verapamil                      
